Advanced search
Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Email Registration
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Calliditas Therapeutics AB (publ)
  6. News
  7. Summary
    CALTX   SE0010441584

CALLIDITAS THERAPEUTICS AB (PUBL)

(CALTX)
  Report
Delayed Nasdaq Stockholm  -  12:29:56 2023-03-24 pm EDT
121.30 SEK   -1.62%
03/13Sector Update: Health Care Stocks Close with Solid Monday Gains
MT
03/13Sector Update: Health Care Maintaining Monday Rebound
MT
03/13Top Midday Gainers
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
 SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Most relevant news about CALLIDITAS THERAPEUTICS AB (PUBL)
03/13Calliditas Therapeutics Shares Jump After Phase 3 Trial of Kidney Disease Treatment Mee..
MT
03/13Calliditas Therapeutics : March 13, 2023 NefIgArd topline data - presentation (Presentatio..
PU
03/13Transcript : Calliditas Therapeutics AB - Special Call
CI
03/13Calliditas Therapeutics Says Phase 3 Trial of Kidney Disease Treatment Met Primary Endp..
MT
03/13Calliditas Drug Maintains Kidney Function Improvements for Two Years in Late-stage Stud..
MT
03/12Calliditas Announces Primary Endpoint Successfully Met in Phase 3 NefIgArd Trial Evalua..
AQ
03/12Calliditas Therapeutics AB Announces Primary Endpoint Successfully Met in Phase 3 NefIg..
CI
03/07Calliditas Therapeutics : March, 2023 Corporate Presentation (Presentation)
PU
03/01Guggenheim Initiates Calliditas Therapeutics at Neutral With $18 Price Target
MT
02/24Calliditas Therapeutics : February, 2023 Corporate Presentation (Presentation)
PU
02/232022 : Successful transformation into a commercial stage company - Form 6-K
PU
02/23Transcript : Calliditas Therapeutics AB, Q4 2022 Earnings Call, Feb 23, 2023
CI
02/23Calliditas Therapeutics AB Provides Earnings Outlook for the Year 2023
CI
02/23Year-End Report, 2022
AQ
02/23Calliditas Therapeutics AB Reports Earnings Results for the Full Year Ended December 31..
CI
More most relevant news
All news about CALLIDITAS THERAPEUTICS AB (PUBL)
03/13Sector Update: Health Care Stocks Close with Solid Monday Gains
MT
03/13Sector Update: Health Care Maintaining Monday Rebound
MT
03/13Top Midday Gainers
MT
03/13Calliditas Therapeutics Shares Jump After Phase 3 Trial of Kidney Disease Treatment Mee..
MT
03/13Calliditas Therapeutics : March 13, 2023 NefIgArd topline data - presentation (Presentatio..
PU
03/13Sector Update: Health Care Stocks Advance in Early Monday Morning Trade
MT
03/13Traders Assess US Moves to Contain Bank Fallout, Prompting Lower Premarket Session for ..
MT
03/13Transcript : Calliditas Therapeutics AB - Special Call
CI
03/13Top Premarket Gainers
MT
03/13Calliditas Therapeutics Says Phase 3 Trial of Kidney Disease Treatment Met Primary Endp..
MT
More news
News in other languages on CALLIDITAS THERAPEUTICS AB (PUBL)
03/13Sector Update : Les soins de santé poursuivent leur rebond de lundi
03/13Les plus fortes hausses de la mi-journée
03/13Les actions de Calliditas Therapeutics bondissent après que l'essai de phase 3 du trait..
03/13Mise à jour sectorielle : Les actions du secteur de la santé pro..
03/13Les traders évaluent les mesures prises par les Etats-Unis pour contenir les retombées ..
03/13Les plus fortes hausses du pré-marché
03/13Les actions en mouvement : les banques, Faurecia, Synlab, et d'..
03/13Calliditas Therapeutics annonce que l'essai de phase 3 de son traitement contre les mal..
03/13Le médicament Calliditas maintient l'amélioration de la fonction rénale pendant deux an..
03/12Calliditas Therapeutics AB annonce que le critère d'évaluation primaire a été atteint a..
More news
Analyst Recommendations on CALLIDITAS THERAPEUTICS AB (PUBL)
03/01Guggenheim Initiates Calliditas Therapeutics at Neutral With $18 Price Target
MT
2021HC Wainwright Adjusts Calliditas Therapeutics' Price Target to $62 From $52, Reiterates..
MT
2021Citigroup Adjusts Calliditas Therapeutics' Price Target to $84 From $51, Reiterates Buy..
MT
2021Analyst recommendations: Alibaba, Goldman Sachs, Monday.com, Sha..
MS
More recommendations
Press releases
03/13Calliditas Therapeutics : March 13, 2023 NefIgArd topline data - presentation (Presentatio..
PU
03/12Calliditas Announces Primary Endpoint Successfully Met in Phase 3 NefIgArd Trial Evalua..
AQ
03/07Calliditas Therapeutics : March, 2023 Corporate Presentation (Presentation)
PU
02/24Calliditas Therapeutics : February, 2023 Corporate Presentation (Presentation)
PU
02/232022 : Successful transformation into a commercial stage company - Form 6-K
PU
More press releases
Upcoming event on CALLIDITAS THERAPEUTICS AB (PUBL)
05/16/23Q1 2023 Earnings Release
Upcoming sector events
04/18/23ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD : FY 2022 Earnings Release
04/26/23ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD : Q1 2023 Earnings Release (Projected)
05/09/23KYOWA KIRIN CO., LTD. : Q1 2023 Earnings Release (Projected)
05/10/23SK BIOPHARMACEUTICALS CO., LTD. : Q1 2023 Earnings Release (Projected)
Sector
Healthcare
Pharmaceuticals & Medical Research
 Pharmaceuticals
  Pharmaceuticals
   Specialty & Advanced Pharmaceuticals
1 MarketScreener is worth more than 1000 Influencers!
100% Free Registration
fermer